Core C: Biospecimen and Biomarker Core

$390,321P50FY2025CANIH

Yale University, New Haven CT

Investigators

Linked publications & trials

Paper 39677793 Paper 39677694 Paper 39386646 Paper 39260448 Paper 39195572 Paper 39155435 Paper 39025895 Paper 38964502 Paper 38857914 Paper 38547779 Paper 38497951 Paper 38481466 Paper 38359163 Paper 38127300 Paper 38060266 Paper 38037567 Paper 38009111 Paper 37977486 Paper 37903180 Paper 37861693 Paper 37806385 Paper 37731001 Paper 37546882 Paper 37541244 Paper 37487666 Paper 37365174 Paper 37343412 Paper 37286865 Paper 37132273 Paper 37121213 Paper 37092028 Paper 36960400 Paper 36925070 Paper 36913537 Paper 36910335 Paper 36889057 Paper 36807383 Paper 36775354 Paper 36631398 Paper 36524727 Paper 36509758 Paper 36357385 Paper 36002182 Paper 35912544 Paper 35882862 Paper 35876281 Paper 35872531 Paper 35793873 Paper 35777367 Paper 35771600 Paper 35660136 Paper 35581307 Paper 35514182 Paper 35490853 Paper 35471840 Paper 35459795 Paper 35443176 Paper 35363784 Paper 35363053 Paper 35338489 Paper 35276062 Paper 35271304 Paper 35252550 Paper 35247929 Paper 35136069 Paper 35087143 Paper 35063942 Paper 35028949 Paper 34897773 Paper 34878717 Paper 34855466 Paper 34852236 Paper 34850062 Paper 34686497 Paper 34670827 Paper 34668345 Paper 34632444 Paper 34597124 Paper 34556846 Paper 34542187 Paper 34518338 Paper 34518312 Paper 34508229 Paper 34493867 Paper 34465600 Paper 34390584 Paper 34381210 Paper 34321321 Paper 34250381 Paper 34174112 Paper 34159859 Paper 34140403 Paper 34088723 Paper 33986041 Paper 33833050 Paper 33804482 Paper 33801444 Paper 33780435 Paper 33707235 Paper 33658301

Abstract

CORE C: SUMMARY The Biospecimen and Biomarker Core C of the Yale SPORE in Lung Cancer (YSILC) has and will focus on the continuous acquisition, processing and analysis of high-quality blood and tissue samples from patients with lung cancer, as well as the development and execution of robust biomarkers to support the main YSILC projects and the Career Enhancement and Developmental Research Programs projects. This shared resource will continue to provide access to unique samples and sample derivatives, perform systematic quality control procedures to secure scientific rigor, enhance the technical skills and capacities beyond the individual projects, and ensure consistency and reproducibility across YSILC activities. The mission of Core C is to maximize the scientific quality and output of the YSILC projects by providing highest quality biospecimens backed up by rigorous molecular analysis using both conventional and next generation technologies. The biospecimen operations will specialize in the acquisition, processing, storage, annotation, quality control and distribution of samples from lung cancer patients including primary (unmodified) specimens and secondary (modified) tumor samples including tissue microarray-based cohorts, âliveâ single cell suspensions and fresh tumor-associated primary explants. The biomarker activities will include providing access to comprehensive biomarker capacities and tissue analysis services including multidimensional quantitative measurements of proteins and nucleic acids from solid and liquid specimens. This Core is co-led by Drs. Kurt Schalper and David Rimm, both with unique and complementary expertise. Dr. Schalper brings knowledge in biospecimen collection, molecular pathology, tumor immunology, correlative clinical trial studies and the generation of ex vivo tumor models. Dr. Rimm brings expertise in quantitative pathology, biospecimen science, spatial biomarkers and regulatory aspects. The specific aims are: Aim 1: To collect, maintain and distribute high quality biospecimens for use in Projects 1-3, Developmental Research and Career Enhancement Programs projects; Aim 2: To develop and distribute advanced secondary biospecimens to support Projects 1-3 and other YSILC activities; and Aim 3: To conduct or assist in molecular pathology analyses of biospecimens including quantitative protein analysis and high-plex discovery.

View original record on NIH RePORTER →